Article
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Molecular cancer - 23 Nov 2011
Alfieri Roberta R, Galetti Maricla, Tramonti Stefano, Andreoli Roberta, Mozzoni Paola, Cavazzoni Andrea, Bonelli Mara, Fumarola Claudia, La Monica Silvia, Galvani Elena, De Palma Giuseppe, Mutti Antonio, Mor Marco, Tiseo Marcello, Mari Ettore, Ardizzoni Andrea, Petronini Pier Giorgio
Abstract excerpt
BACKGROUND: Gefitinib is a tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) especially effective in tumors with activating EGFR gene mutations while EGFR wild-type non small cell lung cancer (NSCLC) patients at present do not benefit from this treatment.The primary site of gefitinib metabolism is the liver, nevertheless tumor cell metabolism can significantly affect treatment...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.